Evaluation of vilazodone for the treatment of depressive and anxiety disorders
Open accessAbstract
INTRODUCTION: Major Depressive Disorder (MDD) and General Anxiety Disorder (GAD) significantly contribute to the global burden of disease. Vilazodone, a combined serotonin reuptake inhibitor and 5-HT1A partial agonist, is an approved therapy for the treatment of MDD and which has been further investigated for GAD. Areas covered: This article covers the pharmacokinetics and pharmacodynamics of vilazodone and provides an evaluation of the clinical usefulness of vilazodone for the treatment of MDD and anxiety disorders. A literature search was performed using PubMed/MEDLINE, Web of Science and the Cochrane Library. Expert opinion: Studies have shown that vilazodone is significantly superior to placebo. However, vilazodone cannot as yet be recommended as a first-line treatment option for MDD as it is unclear whether the drug's dual mechanism of action provides greater efficacy than prevailing treatment options. Moreover, more phase IV studies are needed to establish its efficacy and long-term safety in larger and more diverse populations. Although vilazodone may have an additional advantage for the treatment of anxiety symptoms in MDD, here also additional studies are required to confirm its efficacy over and above SSRI alternatives and other antidepressant treatments. Therefore, presently, vilazodone should be considered as a second- or third-line treatment option for MDD and GAD.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Recent meta-analyses asserted that vilazodone was superior to placebo in the short-term treatment of GAD, with small effect sizes.
“recent meta-analyses asserted that vilazodone was superior to placebo in the short-term treatment of GAD, with small effect sizes (Slee et al., 2019;Stuivenga et al., 2019;Zareifopoulos & Dylja, 2017)”
From Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders (2019) · cites this paper as Stuivenga et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369 · see citing works
The size and burden of mental disorders and other disorders of the brain in Europe 2010
Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jönsson, B., Olesen, J., Allgulander, C., Alonso, J., Faravelli, C., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.018 · Cited by 3,754 · see citing works
(2015) · European Journal Of Haematology · doi:10.1111/ejh.12636 · Cited by 780 · see citing works
The STAR*D project results: A comprehensive review of findings
Warden, D., Rush, A. J., Trivedi, M. H., Fava, M., & Wisniewski, S. R. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0061-3 · Cited by 727 · see citing works
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632 · see citing works
Mechanism of action of serotonin selective reuptake inhibitors
Stahl, S. M. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00221-3 · Cited by 540 · see citing works
Rush, A. J. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.2.201 · Cited by 353 · see citing works
Citrome, L. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02885.x · Cited by 228 · see citing works
LAUGHREN, T. P., Gobburu, J. V. S., Temple, R. J., Unger, E. F., Bhattaram, A., Dinh, P. V., Fossom, L. H., Hung, H., Klimek, V., Lee, J. E., et al. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11r06984 · Cited by 226 · see citing works
Antidepressants and the placebo effect
Kirsch, I. (2014) · Zeitschrift für Psychologie · doi:10.1027/2151-2604/a000176 · Cited by 164 · see citing works
Evidence for Efficacy and Tolerability of Vilazodone in the Treatment of Major Depressive Disorder
Rickels, K., Athanasiou, M., Robinson, D. S., Gibertini, M., Whalen, H., & Reed, C. R. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04637 · Cited by 145 · see citing works
Citrome, L. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12350 · Cited by 140 · see citing works
Khan, A., Cutler, A. J., Kajdasz, D. K., Gallipoli, S., Athanasiou, M., Robinson, D. S., Whalen, H., & Reed, C. R. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06596 · Cited by 130 · see citing works
Hughes, Z. A., Starr, K. R., Langmead, C. J., Hill, M., Bartoszyk, G. D., Hagan, J. J., Middlemiss, D. N., & Dawson, L. A. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.01.018 · Cited by 125 · see citing works
Relevant Issues in the Monitoring and the Toxicology of Antidepressants
Wille, S. M. R., Cooreman, S., Neels, H. M., & Lambert, W. E. (2008) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360701713112 · Cited by 102 · see citing works
Robinson, D. S., Kajdasz, D. K., Gallipoli, S., Whalen, H., Wamil, A., & Reed, C. R. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31822c6741 · Cited by 81 · see citing works
The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder
Sahli, Z. T., Banerjee, P., & Tarazi, F. I. (2016) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1160051 · Cited by 78 · see citing works
Mathews, M., Gommoll, C., Chen, D., Nunez, R., & Khan, A. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000057 · Cited by 77 · see citing works
Efficacy and Safety of Vilazodone in Major Depressive Disorder
Croft, H. A., Pomara, N., Gommoll, C., Chen, D., Núñez, R., & Mathews, M. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m08992 · Cited by 63 · see citing works
Wagner, G., Schultes, M.-T., Titscher, V., Teufer, B., Klerings, I., & Gartlehner, G. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.11.056 · Cited by 61 · see citing works
The Effect of Vilazodone on Sexual Function During the Treatment of Major Depressive Disorder
Clayton, A. H., Kennedy, S. H., Edwards, J. B., Gallipoli, S., & Reed, C. R. (2012) · The Journal of Sexual Medicine · doi:10.1111/jsm.12004 · Cited by 60 · see citing works
Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder
Thase, M. E., Chen, D., Edwards, J., & Ruth, A. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000045 · Cited by 47 · see citing works
Gommoll, C., Durgam, S., Mathews, M., Forero, G., Núñez, R., Tang, X., & Thase, M. E. (2015) · Depression and Anxiety · doi:10.1002/da.22365 · Cited by 44 · see citing works
de Paulis, T. (2007) · PubMed · Cited by 35 · see citing works
A randomized controlled pilot trial of vilazodone for adult separation anxiety disorder
Schneier, F. R., Moskow, D. M., Choo, T.-H., Galfalvy, H., Campeas, R., & Sanchez-Lacay, A. (2017) · Depression and Anxiety · doi:10.1002/da.22693 · Cited by 35 · see citing works
Durgam, S., Chen, C., Migliore, R., Prakash, C., Edwards, J. G., & Findling, R. L. (2018) · Pediatric Drugs · doi:10.1007/s40272-018-0290-4 · Cited by 34 · see citing works
Mechanism of action of the SPARI vilazodone: serotonin 1A partial agonist and reuptake inhibitor
Stahl, S. M. (2014) · CNS Spectrums · doi:10.1017/s1092852914000169 · Cited by 29 · see citing works
Ashby, C. R., Kehne, J. H., Bartoszyk, G. D., Renda, M. J., Athanasiou, M., Pierz, K. A., & Seyfried, C. A. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.07.014 · Cited by 26 · see citing works
Efficacy and Safety of Vilazodone in Patients With Generalized Anxiety Disorder
Durgam, S., Gommoll, C., Forero, G., Núñez, R., Tang, X., Mathews, M., & Sheehan, D. V. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m09885 · Cited by 26 · see citing works
Zareifopoulos, N., & Dylja, I. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.01.016 · Cited by 26 · see citing works
Vilazodone in patients with generalized anxiety disorder
Gommoll, C., Forero, G., Mathews, M., Núñez, R., Tang, X., Durgam, S., & Sambunaris, A. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000096 · Cited by 25 · see citing works
Disposition of Toxic Drugs and Chemicals in Man—11th Edition
Middleberg, R. A. (2017) · Journal of Analytical Toxicology · doi:10.1093/jat/bkx063 · Cited by 24 · see citing works
Eyre, H. A., Siddarth, P., Cyr, N. S., Yang, H., Cole, S. W., Forbes, M., & Lavretsky, H. (2017) · Pharmacopsychiatry · doi:10.1055/s-0043-107033 · Cited by 23 · see citing works
Careri, J. M., Draine, A., Hanover, R., & Liebowitz, M. R. (2015) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.15m01831 · Cited by 19 · see citing works
Dawson, L. A. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.855195 · Cited by 18 · see citing works
Ramaswamy, S., Driscoll, D., Reist, C., Smith, L. M., Albers, L. J., Rose, J., Nguyen, L., Monga, V., Doria, R., & Hollifield, M. (2017) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.17m02138 · Cited by 17 · cited 2× · see citing works
“[25] included patients with a posttraumatic stress disorder (PTSD) in combination with a comorbid depression.”
BackgroundResultDurgam, S., Gommoll, C., Migliore, R., Chen, C., Chang, C.-T., Aguirre, M., & Thase, M. E. (2018) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000236 · Cited by 16 · see citing works
Bathla, M., Anjum, S., Singh, M., Panchal, S., & Singh, G. (2018) · Indian Journal of Psychological Medicine · doi:10.4103/ijpsym.ijpsym_368_17 · Cited by 14 · see citing works
He, H., Wang, W., Lyu, J., Zheng, J., Guo, L., An, X., Fan, Y., & Ma, X. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.10.018 · Cited by 12 · see citing works
Vilazodone efficacy in subgroups of patients with major depressive disorder
Kornstein, S. G., Chang, C., Gommoll, C., & Edwards, J. G. (2018) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000217 · Cited by 10 · see citing works
Rele, S., Millet, R. A., Kim, S., Paik, J., Kim, S. H., Masand, P. S., & Patkar, A. A. (2015) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.14m01734 · Cited by 8 · see citing works
Khan, A., Durgam, S., Tang, X., Ruth, A., Mathews, M., & Gommoll, C. (2016) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.15m01904 · Cited by 6 · see citing works
Double-blind switch study of vilazodone in the treatment of major depressive disorder
Grant, J. E., Redden, S. A., & Leppink, E. W. (2017) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000166 · Cited by 6 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- Laughren TP, Gobburu J, Temple RJ, et al. Vilazodone: clinical basis for the US food and drug administration's approval of a new anti- depressant. J Clin Psychiatry. 2011;72(9):1166-1173.
Cited by
Sorted by citations
Sartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236 · see citing works
Central 5-HT receptors and their function; present and future
Sharp, T., & Barnes, N. M. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108155 · Cited by 227 · see citing works
Antidepressant Medications and Weight Change: A Narrative Review
Gill, H., Gill, B., El‐Halabi, S., Chen-Li, D. C. J., Lipsitz, O., Rosenblat, J. D., Rheenen, T. E. V., Rodrigues, N. B., Mansur, R. B., Majeed, A., et al. (2020) · Obesity · doi:10.1002/oby.22969 · Cited by 197 · see citing works
Zhang, Y., Zheng, G.-X., Fu, T.-T., Hong, J.-J., Li, F.-C., Yao, X.-J., Xue, W., & Zhu, F. (2020) · Physical Chemistry, Chemical Physics - PCCP · doi:10.1039/c9cp05764a · Cited by 29 · see citing works
Boas, G. R. V., Lavorato, S. N., Paes, M. M., Galdino, P. M., Rescia, V. C., Cunha, M. S., de Magalhães-Filho, M. F., Ponsoni, L. F., de Carvalho, A. A. V., de Lacerda, R. B., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14020148 · Cited by 42 · see citing works
Panic Disorder: A Review of Treatment Options
Ziffra, M. (2021) · Annals of Clinical Psychiatry · doi:10.12788/acp.0014 · Cited by 26 · see citing works
Буткевич, И. П., Михайленко, В. А., Vershinina, E. A., & Barr, G. A. (2019) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2019.00125 · Cited by 20 · see citing works
Jia, T., Cao, L., Ye, X., Wei, Q., Xie, W., Cai, C., Dong, Y., Xia, C., Tian, Y., & Wang, K. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112704 · Cited by 16 · see citing works
Zheng, J., Zhou, L., Gong, X., Yang, F., Cheng, J., Ma, R., Wu, C., Xu, Z., Zhu, W., Yang, H., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116564 · Cited by 10 · see citing works
Xu, T., Xue, Y., Lu, J.-L., & Jin, C. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113644 · Cited by 10 · see citing works
Damyard, A., Zahedifar, M., & Akbari, A. (2024) · ChemistrySelect · doi:10.1002/slct.202305221 · Cited by 5 · see citing works
Han, X.-M., Huang, F., Jiao, M., Liu, H., Zhao, Z., Zhan, H., & Guo, S. (2020) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b20-00093 · Cited by 5 · see citing works
Wang, Z.-Z., Yi, C., Huang, J., Xu, T., Chen, K.-Z., Wang, Z., Xue, Y., Lu, J.-L., Nie, B., Zhang, Y., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01339 · Cited by 5 · see citing works
Multitarget-Directed Ligands Hitting Serotonin Receptors: A Medicinal Chemistry Survey
Idrissi, I. G. E., Santo, A., Lacivita, E., & Leopoldo, M. (2024) · Pharmaceuticals · doi:10.3390/ph17091238 · Cited by 4 · see citing works
Evidence-Based Pharmacotherapies for Panic Disorder
Norrholm, S. D. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106205 · Cited by 2 · see citing works
Prescribing Antidepressant Medication
Kroll, D. S. (2022) · Springer eBooks · doi:10.1007/978-3-031-08495-9_3 · Cited by 1 · see citing works
Sadek, J. R. (2020) · Springer eBooks · doi:10.1007/978-3-030-60766-1_2 · Cited by 1 · see citing works
Tan, X.-G., Liu, X.-F., Li, X., Wang, Y.-Q., Wang, Y.-Q., & Zhao, Y. (2023) · Chinese Physics B · doi:10.1088/1674-1056/acd687 · Cited by 1 · see citing works
Introductory Chapter: Antidepressants - Preclinical, Clinical and Translational Aspects
Olivier, B. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.86476
Motta, R. W. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.102252
Managing Risks and Side Effects of Antidepressant Medications
Kroll, D. S. (2022) · Springer eBooks · doi:10.1007/978-3-031-08495-9_4
Johnston, C. H., Majoka, M. A., Macaluso, M., & Wilkinson, S. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894551913.lg02
- Authors
- Stuivenga, M., Giltay, E. J., Cools, O., Roosens, L., Neels, H., & Sabbe, B.
- Affiliations
- University of Antwerp (BE)
- Corresponding author
- Stuivenga, Mirella
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2018-11-26
- Volume
- 20
- Issue
- 3
- Pages
- 251-260
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2902249788
- Cited by
- 24
- References
- 43
- Citations by year
- 2025: 1 · 2024: 5 · 2023: 2 · 2022: 4 · 2021: 3 · 2020: 6 · 2019: 3
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- Locations
- Expert Opinion on Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- vilazodone, major depressive disorder, generalized anxiety disorder, serotonin reuptake inhibitors, pharmacokinetics, pharmacodynamics, antidepressant efficacy, long-term safety, second-line therapy
- MeSH terms
- Vilazodone Hydrochloride, Animals, Antidepressive Agents, Anxiety Disorders, Major Depressive Disorder, Depressive Disorder, Major, Humans, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
